Clin Osteol 2025; 30(4): 226-231

Biosimilar denosumab - a new chapter in the treatment of bone diseasesSaid at the congress

doc. MUDr. Karel Urbánek, Ph.D., prof. MUDr. Vladimír Palička, CSc., dr.h.c., prof. MUDr. Karel Pavelka, DrSc.
Přednášeli v rámci firemního sympozia společnosti Celltrion na mezinárodním kongresu českých slovenských osteologů který se konal 11.-13. září 2025

Biosimilar medicines, which are biologically similar to the reference product, although not identical copies, reduce the cost of biological treatment and make it possible to expand the number of patients who can receive it. There is sufficient evidence that the efficacy of biosimilar medicines does not differ from that of the original biological products and that switching from the original medicine to a biosimilar, as well as between biosimilars, is not only feasible but also safe.

Keywords: biosimilar, denosumab, osteoporosis.

Published: December 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánek K, Palička V, Pavelka K. Biosimilar denosumab - a new chapter in the treatment of bone diseases. Clinical Osteology. 2025;30(4):226-231.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 50 CZK
    will be unlocked 1.12.2026

    References

    1. Barbier L, Ebbers HC, Declerck P, et al. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clin Pharmacol Ther. 2020 Oct;108(4):734-755. doi: 10.1002/cpt.1836. Go to original source...
    2. Kurki P, Barry S, Bourges, et al. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs. 2021 Nov;81(16):1881-1896. doi: 10.1007/s40265-021-01601-2. Go to original source...
    3. Souhrn informací o přípravku Stoboclo, www.ema.europa.eu/cs/documents/product-information/stoboclo-epar-product-information_cs.pdf
    4. Kim A, Hong JH, Shin W, et al. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert Opin Biol Ther. 2024 Jul;24(7):655-663. doi: 10.1080/14712598.2024.2316846. Go to original source...
    5. Reginster JY, Czerwinski E, Wilk K, et al. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. Osteoporos Int. 2024 Nov;35(11):1919-1930. doi: 10.1007/s00198-024-07161-x. Go to original source...
    6. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017 Feb;76(2):355-363. doi: 10.1136/annrheumdis-2015-208786. Go to original source...
    7. Jørgensen KK, Olsen IC, Goll GL, et al. NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Erratum in: Lancet. 2017 Jun 10;389(10086):2286. doi: 10.1016/S0140-6736(17)31423-X. Go to original source...
    8. Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Go to original source...
    9. Smolen JS, Caporali R, Doerner T, et al. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. RMD Open. 2021 Jun;7(2):e001637. doi: 10.1136/rmdopen-2021-001637. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.